according to the Globally Harmonized System



Rizatriptan Formulation

Revision Date: Date of last issue: 04.04.2023 Version SDS Number: 06.04.2024 407397-00018 Date of first issue: 10.12.2015 3.1

1. PRODUCT AND COMPANY IDENTIFICATION

Product name Rizatriptan Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address 30 Hudson Street, 33nd floor

Jersey City, New Jersey, U.S.A 07302

Telephone : +1-551-430-6000

Emergency telephone number: +1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use Pharmaceutical Restrictions on use Not applicable

2. HAZARDS IDENTIFICATION

Manufacture, Storage and Import of Hazardous Chemicals Rules 1989

Classification

Not classified as hazardous according to criteria laid down in Part I of Schedule-1.

GHS Classification

Reproductive toxicity Category 2

repeated exposure (Oral)

Specific target organ toxicity - : Category 2 (Cardio-vascular system)

GHS label elements

Hazard pictograms

Signal word

Hazard statements H361d Suspected of damaging the unborn child.

H373 May cause damage to organs (Cardio-vascular system)

through prolonged or repeated exposure if swallowed.

Precautionary statements Prevention:

P203 Obtain, read and follow all safety instructions before use.

according to the Globally Harmonized System



Rizatriptan Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

P260 Do not breathe dust.

P280 Wear protective gloves/ protective clothing/ eye protec-

tion/ face protection.

Response:

P318 IF exposed or concerned, get medical advice.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste

disposal plant.

Other hazards which do not result in classification

Dust contact with the eyes can lead to mechanical irritation.

Contact with dust can cause mechanical irritation or drying of the skin.

May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (%
		w/w)
Cellulose	9004-34-6	>= 50 - < 70
Starch	9005-25-8	>= 10 - < 20
Rizatriptan	145202-66-0	>= 5 - < 10

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty

of water.

Remove contaminated clothing and shoes.

Get medical attention. Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

Most important symptoms

and effects, both acute and

delayed

: Suspected of damaging the unborn child.

May cause damage to organs through prolonged or repeated

exposure if swallowed.

Contact with dust can cause mechanical irritation or drying of

the skin.

according to the Globally Harmonized System



Rizatriptan Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician : Treat symptomatically and supportively.

5. FIREFIGHTING MEASURES

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical None known.

Unsuitable extinguishing

media

Specific hazards during fire-

fighting

Avoid generating dust; fine dust dispersed in air in sufficient

concentrations, and in the presence of an ignition source is a

potential dust explosion hazard.

Exposure to combustion products may be a hazard to health.

Hazardous combustion prod-

ucts

Carbon oxides

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emer-

gency procedures

Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

Methods and materials for containment and cleaning up

Sweep up or vacuum up spillage and collect in suitable container for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.

Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

according to the Globally Harmonized System



Rizatriptan Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation
Advice on safe handling

Use only with adequate ventilation.

Do not breathe dust. Do not swallow.

Avoid contact with eyes.

Avoid prolonged or repeated contact with skin.

Wash skin thoroughly after handling.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the

environment.

Conditions for safe storage

Keep in properly labelled containers.

Store locked up.

Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:

Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of	Control parameters / Permissible	Basis
		exposure)	concentration	
Cellulose	9004-34-6	TWA	10 mg/m3	ACGIH
Starch	9005-25-8	TWA	10 mg/m3	ACGIH
Rizatriptan	145202-66-0	TWA	10 μg/m3 (OEB 3)	Internal
		Wipe limit	100 μg/100 cm ²	Internal

Engineering measures : All eng

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to

protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face contain-

ment devices).

Minimize open handling.

according to the Globally Harmonized System



Rizatriptan Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection.

Filter type
Hand protection

Particulates type

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Eye protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable

suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working

place.

When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : pink

Odour : odourless

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flash point : Not applicable

Evaporation rate : No data available

according to the Globally Harmonized System



Rizatriptan Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 04.04.2023

 3.1
 06.04.2024
 407397-00018
 Date of first issue: 10.12.2015

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

Vapour pressure : No data available

Relative vapour density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle characteristics

Particle size : No data available

10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard. Chemical stability : Stable under normal conditions.

Possibility of hazardous reac-

tions

May form explosive dust-air mixture during processing, han-

dling or other means.

Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

Oxidizing agents

Incompatible materials

Hazardous decomposition

products

No hazardous decomposition products are known.

according to the Globally Harmonized System



Rizatriptan Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

11. TOXICOLOGICAL INFORMATION

Information on likely routes of : Inhalation

exposure Skin contact

Ingestion Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg

Method: Calculation method

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Rizatriptan:

Acute oral toxicity : LD50 (Rat): 2,227 mg/kg

LD50 (Mouse): 700 - 1,631 mg/kg

Skin corrosion/irritation

Not classified based on available information.

Components:

Rizatriptan:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Starch:

Species : Rabbit

Result : No eye irritation

according to the Globally Harmonized System



Rizatriptan Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

Rizatriptan:

Species : Bovine cornea

Remarks : Moderate eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:

Starch:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Rizatriptan:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Assessment : Does not cause skin sensitisation.

Result : negative

Germ cell mutagenicity

Not classified based on available information.

Components:

Cellulose:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo

cytogenetic assay) Species: Mouse

Application Route: Ingestion

Result: negative

Starch:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Rizatriptan:

according to the Globally Harmonized System



Rizatriptan Formulation

Revision Date: Date of last issue: 04.04.2023 Version SDS Number: 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

Genotoxicity in vitro Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Alkaline elution assay

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo Test Type: Mammalian erythrocyte micronucleus test (in vivo

> cytogenetic assay) Species: Mouse Application Route: Oral

Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Cellulose:

Species Rat Application Route : Ingestion Exposure time : 72 weeks Result : negative

Rizatriptan:

Species : Mouse Application Route : Oral : 100 weeks Exposure time

NOAEL : 125 mg/kg body weight

Result : negative

Rat Species Application Route Oral

Exposure time 106 weeks

NOAEL 106 mg/kg body weight

negative Result

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

Cellulose:

Effects on fertility Test Type: One-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

according to the Globally Harmonized System



Rizatriptan Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

Effects on foetal develop-

ment

Test Type: Fertility/early embryonic development

Species: Rat

Application Route: Ingestion

Result: negative

Rizatriptan:

Effects on fertility : Test Type: Fertility/early embryonic development

Species: Rat, female Application Route: Oral

Fertility: LOAEL: 100 mg/kg body weight

Symptoms: altered estrus cycles

Result: No effects on fertility and early embryonic develop-

ment were detected.

Test Type: Fertility/early embryonic development

Species: Rat, male Application Route: Oral

Fertility: NOAEL: 250 mg/kg body weight

Result: No effects on fertility and early embryonic develop-

ment were detected.

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: No teratogenic effects, Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: No teratogenic effects, Embryo-foetal toxicity

Remarks: The effects were seen only at maternally toxic dos-

es.

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

Components:

Rizatriptan:

Assessment : May cause drowsiness or dizziness.

STOT - repeated exposure

May cause damage to organs (Cardio-vascular system) through prolonged or repeated exposure if swallowed.

according to the Globally Harmonized System



Rizatriptan Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

Components:

Rizatriptan:

Target Organs : Cardio-vascular system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

Cellulose:

Species : Rat

NOAEL : >= 9,000 mg/kg

Application Route : Ingestion Exposure time : 90 Days

Starch:

Species : Rat

NOAEL : >= 2,000 mg/kg Application Route : Skin contact

Exposure time : 28 Days

Method : OECD Test Guideline 410

Rizatriptan:

Species : Rat
LOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 14 Weeks

Symptoms : Dilatation of the pupil, Increased pulse rate, Redness

Species : Dog

LOAEL : 0.05 mg/kg
Application Route : Intravenous
Exposure time : 2 Weeks

Symptoms : Dilatation of the pupil, Increased pulse rate, Redness

Species : Dog
LOAEL : 0.2 mg/kg
Application Route : Oral
Exposure time : 1 yr

Symptoms : Dilatation of the pupil

Aspiration toxicity

Not classified based on available information.

Experience with human exposure

Components:

Rizatriptan:

Ingestion : Target Organs: Cardio-vascular system

according to the Globally Harmonized System



Rizatriptan Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

Symptoms: asthenia, Fatigue, Pain, Dizziness, Weakness,

Drowsiness

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Cellulose:

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l

Exposure time: 48 h

Remarks: Based on data from similar materials

Rizatriptan:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 1,000 mg/l

Exposure time: 48 h

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): > 100

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 48

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50: > 1,000 mg/l

Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

NOEC: 1,000 mg/l Exposure time: 3 h

Test Type: Respiration inhibition Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 9.6 mg/l

Exposure time: 32 d

Species: Pimephales promelas (fathead minnow)

Method: OECD Test Guideline 210

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 110 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

according to the Globally Harmonized System



Rizatriptan Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

Persistence and degradability

Components:

Cellulose:

Biodegradability : Result: Readily biodegradable.

Rizatriptan:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 50 % Exposure time: 13 d

Method: OECD Test Guideline 314

Bioaccumulative potential

Components:

Rizatriptan:

Partition coefficient: n-

octanol/water

log Pow: -0.649

Mobility in soil

Components:

Rizatriptan:

Distribution among environ-

mental compartments

ng environ- : log Koc: 3.83

Method: OECD Test Guideline 106

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues : Do not dispose of waste into sewer.

Dispose of in accordance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

14. TRANSPORT INFORMATION

International Regulations

UNRTDG

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

according to the Globally Harmonized System



Rizatriptan Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

Not regulated as a dangerous good

Transport in bulk according to IMO instruments

Not applicable for product as supplied.

Special precautions for user

Not applicable

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

: Internal technical data, data from raw material SDSs, OECD

eChem Portal search results and European Chemicals Agen-

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 06.04.2024

Further information

Sources of key data used to compile the Safety Data

Sheet cy, http://echa.europa.eu/

Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation: DSL - Domestic Substances List (Canada): ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect

according to the Globally Harmonized System



Rizatriptan Formulation

Version Revision Date: SDS Number: Date of last issue: 04.04.2023 3.1 06.04.2024 407397-00018 Date of first issue: 10.12.2015

Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IN / EN